tbuckley/cabot-search huggingface dataset:
A pilot study to establish non-invasive biomarkers for higher-grade meningioma
Authors: Daniele Baiz, Caterina Negroni, Emanuela Ercolano, Claire L Adams, Kathreena M Kurian, David A Hilton, Oliver C Hanemann
Journal: Neuro-Oncology (2019)

Abstract Introduction Meningioma brain tumours are the most common primary tumour in adults. Despite surgery and/or radiation therapy, meningioma may recur. The 5-year recurrence rate in benign meningioma is estimated in about 10% while much greater in atypical and malignant tumours. MicroRNAs (miRNAs) represent a large class of small RNAs driving regulation of gene expression and playing a role in tumour progression and therefore proposed as diagnostic tools. Moreover, miRNAs can be released from tumour cells into the blood stream via exosomes, showing potential to be used as liquid biopsies. Methods Identification of novel circulating biomarkers was conducted by performing an unbiased Cancer MicroRNA qPCR Array, followed by bioinformatics analysis. In parallel, we conducted a biased in silico analysis of the miRNAs targeting Cyclin D1 and E1, recently proposed as immunohistochemical meningioma biomarkers. Validation studies performed using TaqMan® reagents. Results Stringent unbiased (p&lt;0.01) miRNA profiling followed by validation in ex vivo samples revealed that the miR-9-1 is upregulated in higher-grade meningioma tissues and serum exosomes, controlled by the EGFR/AP-1 axis and correlated with lower levels of E-Cadherin, a proposed biomarker for malignant meningioma. On the contrary, biased analysis, followed by validation in vitro and ex vivo, showed that the miR-497~195 cluster is downregulated in higher-grade meningioma tissues and serum exosomes, correlating with the overexpression of GATA-4, a novel meningioma tissue biomarker. Conclusion Our data demonstrated that both miR-497~195 and miR-9-1 show potential to become promising non-invasive biomarkers for higher-grade meningioma, reflecting their expression status in tissues. (DB and CN contributed equally).
Crispr-Cas9 Mediated Disruption of Dnmt3a in JakV617F Hematopoietic Stem Cells Accelerates Disease Phenotype and Induces Lethal Myelofibrosis
Authors: Sebastien Jacquelin, Emma Dishington, Therese Vu, Axia Song, Matthew Heidecker, Solene Guignes, Claudia Bruedigam, Joanne Sutton, Geoffrey R Hill, Nicole Cloonan, Dirk Heckl, Steven W Lane
Journal: Blood (2016)
Post–Liver Transplantation Sinusoidal Obstruction Syndrome With Refractory Ascites Induced by Mycophenolate Mofetil
Authors: Edoardo Poli, Ilias Kounis, Catherine Guettier, Céline Verstuyft, Audrey Coilly, Rodolphe Sobesky, Cyrille Feray, Eric Vibert, Oriana Ciacio, Didier Samuel, Henri Bismuth, Jean‐Charles Duclos‐Vallée
Journal: Hepatology (2019)
Hemopoietic Progenitor Cells from the Bone Marrow of Serpinb3A-/- Mice Are Radioresistant
Authors: Stephanie Thermozier, Michael W. Epperly, Darcy Franicola, Xichen Zhang, Renee Fisher, Donna Shields, Hong Wang, John A. Willis, Cliff Luke, Gary A. Silverman, Joel S. Greenberger
Journal: Blood (2016)
Monocytic Myeloid Derived Suppressor CELLS (M-MDSC) As Prognostic Factor in Chronic Myeloid Leukemia Patients Treated with Dasatinib
Authors: Cesarina Giallongo, Nunziatina L Parrinello, Daniele Tibullo, Piera La Cava, Alessandra Romano, Annalisa Chiarenza, Fabio Stagno, Paolo Vigneri, Giuseppe A Palumbo, Francesco Di Raimondo, Claudia Bellofiore
Journal: Blood (2015)
Defibrotide (DF) in the Treatment of Severe Hepatic Veno-Occlusive Disease (VOD) with Multi-Organ Failure (MOF) Following Stem Cell Transplantation (SCT): Results of a Phase 3 Study Utilizing a Historical Control.
Authors: Paul Richardson, Marcie Tomblyn, Nancy Kernan, Joel A. Brochstein, Shin Mineishi, Amanda Termuhlen, Sally Arai, Stephan A. Grupp, Eva Guinan, Paul L. Martin, Selim Corbacioglu, Ernst Holler, Ralph D'Agostino, Joseph Massaro, Alison L. Hannah, Massimo Iacobelli, Robert J Soiffer
Journal: Blood (2009)
Haploinsufficiency Of SAMD9L, An Endosome Fusion Facilitator, In Mice Induces The Development Of Myeloid Malignancies Mimicking Human Diseases With Monosomy 7
Authors: Hirotaka Matsui, Akiko Nagamachi, Akinori Kanai, Yuko Ozaki, Hiroaki Honda, Toshiya Inaba
Journal: Blood (2013)
Impact of Time from Diagnosis to Initiation of Curative-Intent Chemotherapy on Clinical Outcomes in Patients with Hodgkin Lymphoma
Authors: Edward G. Brooks, Joseph M. Connors, Laurie H. Sehn, Randy D. Gascoyne, Kerry J. Savage, Tamara Shenkier, Richard Klasa, Alina S. Gerrie, Brian Skinnider, Graham Slack, Diego Villa
Journal: Blood (2013)
ZD6474 versus gefitinib in patients with advanced NSCLC: Final results from a two-part, double-blind, randomized phase II trial
Authors: R. B. Natale, D. Bodkin, R. Govindan, B. Sleckman, N. Rizvi, A. Capo, P. Germonpré, P. Stockman, S. Kennedy, M. Ranson
Journal: Journal of Clinical Oncology (2006)

7000 Background: ZD6474 is a once-daily oral agent that targets key signaling pathways in cancer by inhibiting VEGF, EGF and RET receptor tyrosine kinase activity. The efficacy and safety of ZD6474 was compared with that of gefitinib, an EGFR tyrosine kinase inhibitor. Methods: Patients with locally advanced or metastatic (stage IIIB/IV) non-small-cell lung cancer (NSCLC), after failure of 1st-line ± 2nd-line platinum-based chemotherapy because of toxicity or tumor progression, received daily oral doses of ZD6474 (300 mg) or gefitinib (250 mg) until disease progression or evidence of toxicity (Part A). After a washout period of 4 weeks, eligible patients had the option to switch to the alternative treatment, which continued until a withdrawal criterion was met (Part B). The dual primary objectives in Part A were assessments of progression-free survival (PFS) and safety/tolerability. All adverse events were assessed using Common Toxicity Criteria (CTC) version 2.0. Results: A total of 168 patients received initial treatment with ZD6474 (n=83) or gefitinib (n=85). In Part A, median PFS was 11.0 weeks for ZD6474 and 8.1 weeks for gefitinib (hazard ratio [95% CI] = 0.69 [0.50–0.96], P=0.025); disease control &gt;8 weeks was achieved in 37/83 (45%) patients receiving ZD6474 and in 29/85 (34%) receiving gefitinib. The adverse event profile of ZD6474 in Part A was similar to that seen in previous trials, and included diarrhea (CTC grade 3/4, 8.4%), rash (CTC grade 3/4, 4.8%) and asymptomatic QTc prolongation (all CTC grade 1, 20.5%). There were no unexpected safety findings with gefitinib-treated patients. In Part B, disease control &gt;8 weeks was achieved in 16/37 patients who switched to ZD6474 (from gefitinib) and in 7/29 who switched to gefitinib (from ZD6474). Overall survival was not significantly different between patients initially randomized to either ZD6474 or gefitinib (median 6.1 and 7.4 months, respectively). Conclusions: This study achieved its primary efficacy objective, with ZD6474 demonstrating a significant prolongation of PFS versus gefitinib. These data support further confirmatory trials of ZD6474 in patients with advanced NSCLC. [Table: see text]
The bacteria which were detected by blood culture of 2015-2017: Mouth care and bacteremia during anticancer therapy
Authors: Yumi Jo, Junji Suzumiya, Fumiyoshi Ikejiri, Fumimasa Takahashi, Takahiro Okada, Masaya Inoue, Ichiro Moriyama, Tsutomu Takahashi, Takaaki Miyake, Ritsuro Suzuki
Journal: Annals of Oncology (2019)
Combined Effects of Novel Heat Shock Protein 90 Inhibitor NVP-AUY922 and Nilotinib against Mutant Forms of BCR-ABL
Authors: Tetsuzo Tauchi, Daigo Akahane, Seiichi Okabe, Eishi Ashihara, Shinya Kimura, Taira Maekawa, Kazuma Ohyashiki
Journal: Blood (2008)
Phase I/II Study of Vosaroxin and Decitabine in Newly Diagnosed Older Patients (pts) with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)
Authors: Daver Naval, Hagop M. Kantarjian, Guillermo Garcia-Manero, Naveen Pemmaraju, Tapan M. Kadia, Courtney D. DiNardo, Nitin Jain, Gautam Borthakur, Elias Jabbour, Marina Konopleva, Jorge E. Cortes, Adam Craig, Farhad Ravandi
Journal: Blood (2014)
Clinical Characteristics and Outcomes of Limited-Stage Primary Extranodal Versus Nodal Diffuse Large B-Cell Lymphoma (DLBCL) in Thailand: A Nationwide Multi-Institutional Registry of 920 Cases in Thailand
Authors: Lalita Norasetthada, Weerasak Nawarawong, Arnuparp Lekhakula, Jakrawadee Julamanee, Chittima Sirijerachai, Kanchana Chansung, Kitsada Wudhikarn, Udomsak Bunworasate, Noppadol Siritanaratanakul, Archrob Khuhapinant, Tontanai Numbenjapon, Kannadit Prayongratana, Tawatchai Suwanban, Suporn Chuncharunee, Pimjai Niparuck, Somchai Wongkhantee, Peerapon Wong, Nisa Makruasi, Nonglak Kanitsap, Tanin Intragumtornchai
Journal: Blood (2015)
Activation of HIF-2a-EPO Axis in Kidney or Liver Is Sufficient to Drive Erythrocytosis in a Novel Inducible HIF-2a Transgenic Mouse Model
Authors: Jieyu Wang, Yoshihiro Hayashi, Zefeng Xu, Lingyun Wu, Xiaomei Yan, Theodosia A. Kalfa, Zhijian Xiao, Gang Huang
Journal: Blood (2015)
Ex Vivo Graft Purging and Expansion of Autologous Mobilized Peripheral Blood Progenitor Cell (PBPC) Products from Patients with Multiple Myeloma (MM).
Authors: Hong Yang, Simon N. Robinson, Yago Nieto, Sergio A. Giralt, Roy B. Jones, William K. Decker, Dongxia Xing, David Steiner, Richard E. Champlin, Jingjing Ng, Michael W. Thomas, Marcos de Lima, Elizabeth J. Shpall
Journal: Blood (2007)
Abstract 15475: Illness Identity and Its Association With Absence at Work or School in Adults With Congenital Heart Disease
Authors: Liesbet Van Bulck, Koen Luyckx, Eva Goossens, Leen Oris, Silke Apers, Philip Moons
Journal: Circulation (2018)

Introduction: Absence at work or school greatly affects chronically ill patients and society. Research on modifiable predictors of absence at work or school is limited. A concept that could be of r...
Detection of Non Inhibitory Binding Antibodies to Von Willebrand Factor Affecting the Clearance of VWF:Ag in Von Willebrand Disease
Authors: Tobias M Suiter, Pier Mannuccio Mannucci, Christine L Kempton, Michael Laffan, Edward H Romond, Amy D. Shapiro, Ingvild Birschmann, Margaret V. Ragni, Joan Cox Gill, Thynn Thynn Yee, Robert Klamroth, Frank M Horling, Birgit M Reipert, Peter L Turecek, Katalin Varadi, Miranda Chapman, Werner Engl, Wing Yen Wong, Bruce M. Ewenstein
Journal: Blood (2011)
The Immunohistochemical Profile and Other Prognostic Factors In Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma Treated with R-CHOP
Authors: Jorge J Castillo, Brady Beltran, Joo-Seop Chung, Ivana Ilic, Sirpa Leppa, Ritsuko Seki, Silvia Uccella, Zu-Guang Xia, James N Butera
Journal: Blood (2010)
The Expression of Human Leukocyte Formin Protein, a New Protein That Associates with AKT, Is Correlated with the Expression of ZAP-70 in CLL.
Authors: Patricia M.B. Favaro, Samuel S. Medina, Fabiola Traina, Gislaine B. Oliveira, Irene L. Metze, Fernando F. Costa, Sara T.O. Saad
Journal: Blood (2004)
In Acute Myeloid Leukemia with Complex Karyotype TP53 Alterations Are Associated with Specific Genomic Aberrations and Predict Inferior Survival.
Authors: Frank G Rücker, Richard F Schlenk, Lars Bullinger, Helena Kett, Annegret Becker, Carla-Maria Kugler, Thorsten Zenz, Peter Lichter, Jürgen Krauter, Brigitte Schlegelberger, Arnold Ganser, Hartmut Döhner, Konstanze Döhner
Journal: Blood (2009)
The Impact of Colonization with Multidrug-Resistant Bacterial Pathogens (MRP) in Allogeneic Hematopoietic Cell Transplantation - Clearance of the MRP Is Pivotal for Survival
Authors: Daniela Heidenreich, Sebastian Kreil, Klaus-Peter Becker, Thomas Miethke, Wolf-Karsten Hofmann, Stefan A. Klein
Journal: Blood (2016)
17p Deletion Is the Most Frequent Abnormality Acquired During Clonal Evolution in Chronic Lymphocytic Leukemia (CLL): 429 Cases Analyzed by Interphase FISH and Chromosome Banding Analysis,
Authors: Claudia Haferlach, Melanie Zenger, Susanne Schnittger, Wolfgang Kern, Torsten Haferlach
Journal: Blood (2011)
Allogeneic Stem Cell Transplantation for Blast Crisis (BC) Chronic Myelogenous Leukemia (CML) In the Tyrosine Kinase Inhibitors (TKIs) Era. Analysis of Pre-Transplant Variables on Transplant Outcome. On Behalf of the Societe Française De Greffe De Moelle Et De Therapie Cellulaire and the French Group of CML
Authors: Franck Nicolini, Laurent Modolo, Nicole Raus, Noel Milpied, Gerard Socie, Ibrahim Yakoub-Agha, Mohamad Mohty, Nathalie Fegueux, Herve Tilly, Didier Blaise, Pierre Bordigoni, Karin Bilger, Catherine Cordonnier, Jean-Hugues Dalle, Thierry De Revel, Eric Deconninck, Bernard Rio, Anne Sirvent, Norbert Ifrah, Gaelle Guillerm, Valerie Mialou, Agnes Buzyn, Anne Huynh, Jacques-Olivier Bay, Stephane Morisset, Mauricette Michallet
Journal: Blood (2010)
Partha Kar: Recalibrating the four hour target
Authors: Partha Kar
Journal: BMJ (2019)

It’s nearly that time of the year again—or at least it used to be. Now the drive to “improve flow” is pretty much a year round phenomenon. And what started as a well intentioned goal of ensuring that 95% of patients attending emergency departments were admitted, transferred, or discharged within four hours has become a tool for measuring the success of departments, hospitals, and trusts. The “four hour target” has become a political football, and views about its use are becoming ever more sharply polarised.

The problem, as ever, is not the target itself but the NHS’s obsession with following it like a moth to a flame. Hospital after hospital has …
Polymorphisms In Signal Transducer and Activator of Transcription 5 (STAT5) and Response to Cytarabine-Based Chemotherapy In Acute Myeloid Leukemia Patients
Authors: Bao-An Chen, Yue-jiao Zhong, Ji-feng Feng, Lu Cheng, Yu-feng Li, Jun Qian, Jia-hua Ding, Feng Gao, Guo-hua Xia, Zuhong Lu, Jian Cheng, Wen Bao
Journal: Blood (2010)
Cerebral Blood Flow Measurement in Children with Sickle Cell Disease Using CASL at 3.0 Tesla MRI
Authors: Xandra W. van den Tweel, Aart J. Nederveen, Charles B.L.M. Majoie, Johanna H. van der Lee, Laetitia Wagener-Schimmel, Marianne A.A. Walderveen, Bwee Tien Poll The, Paul J. Nederkoorn, Harriet Heijboer, Karin Fijnvandraat
Journal: Blood (2008)
Obinutuzumab plus Bendamustine Followed by Obinutuzumab Maintenance Prolongs Overall Survival Compared with Bendamustine Alone in Patients with Rituximab-Refractory Indolent Non-Hodgkin Lymphoma: Updated Results of the GADOLIN Study
Authors: Bruce D. Cheson, Marek Trněný, Kamal Bouabdallah, Gregory Dueck, John Gribben, Pieternella J Lugtenburg, Oliver Press, Gilles A. Salles, Günter Fingerle-Rowson, Federico Mattiello, Elisabeth Wassner-Fritsch, Laurie H Sehn
Journal: Blood (2016)
Circulating B-Lymphocyte Subpopulations as Novel Biomarker for Measuring Activity of Chronic Graft-Versus-Host Disease.
Authors: David Pohlreich, Hildegard T. Greinix, Karin Feldmann, Ulrike Koermoeczi, Imke Lohmann, Margit Mitterbauer, Peter Kalhs, Werner Rabitsch, Christoph Zielinski, Winfried F. Pickl
Journal: Blood (2006)
Allogeneic Transplantation for Chronic Myelomonocytic Leukemia (CMML) Is Associated with High Disease-Free Survival Even in the Setting of High-Risk Disease
Authors: Matias Eugenio Sanchez, Kamal Kant Singh Abbi, Roni Tamari, Ann Jakubowsky, Esperanza B Papadopoulos, Sean M. Devlin, Weiji Shi, Craig S. Sauter, Juliet N. Barker, Farid Boulad, Sergio Giralt, Richard Meagher, Hugo Castro-Malaspina
Journal: Blood (2014)
The Candida albicans exotoxin candidalysin promotes alcohol-associated liver disease
Authors: Huikuan Chu, Yi Duan, Sonja Lang, Lu Jiang, Yanhan Wang, Cristina Llorente, Jinyuan Liu, Selene Mogavero, Francisco Bosques-Padilla, Juan G. Abraldes, Victor Vargas, Xin M. Tu, Ling Yang, Xiaohua Hou, Bernhard Hube, Peter Stärkel, Bernd Schnabl
Journal: Journal of Hepatology (2019)
Isolation and Functional Characterization of a Novel “Oxidative State – low” Leukemic Population with Stem Cell Properties and Potential Resistance to Chemotherapy In Acute Myeloid Leukemia.
Authors: Eleni D. Lagadinou, Dimitra Kokkinou, Elena Siapati, George Vassilopoulos, Craig T. Jordan, Alexandros Spyridonidis
Journal: Blood (2010)
Tinzaparine in the Management of Painful Vaso-Occlusive Crisis of Sickle Cell Anaemia.
Authors: Mohamad H. Qari, Shaker Mousa, Mohamad A. Alsaigh, Panagiotis Zografos, Suad K. Aljaouni, Huda Fatani, Adnan Alalfi, Fatin M. Alsayes, Basim T. Beirouti, Mohamad A. Alamin, Abdulilah Gadi
Journal: Blood (2005)
Immunomodulatory Drugs Inhibit H2O2 Decomposition in Multiple Myeloma Cells and Its Mediated Cytotoxicity Is Determined By Cellular Antioxidative Capacity
Authors: Sinto Sebastian Chirackal, Yuan Xiao Zhu, Esteban Braggio, Chang-Xin Shi, Sonali Panchabhai, Gregory Ahmann, Scott A. Van Wier, Marta Chesi, Leif Bergsagel, Keith Stewart, Rafael Fonseca
Journal: Blood (2015)
Study on the Efficacy and Safety of Non-Factor Drugs Applied the Etiological Classification for Treatment of Hemophilia:a Multi-Centre, Prospective Single-Arm Clinical Trial
Authors: Shanxi Liu, Yanfeng Xiao, Jun Lv, Qingbo Liu, Pengbo Li, Penghui Wang, Yiguo Liu, Peggy (Pei-Hua) Lu
Journal: Blood (2016)
A Novel Intermediate Intensity Conditioning Regimen Achieves High Rates of Long-Term Outpatient Progression-Free Survival Offsetting the Disadvantage of Early Post-Transplant Complications in Adult Cord Blood (CB) Transplant Recipients
Authors: Ioannis Politikos, Sean Devlin, Yeon Yoo, Christopher Mazis, Molly A. Maloy, Andromachi Scaradavou, Parastoo B. Dahi, Miguel Perales, Sergio Giralt, Doris M Ponce, Juliet N. Barker
Journal: Blood (2016)
Effects of Genetic Polymorphisms on Leukocyte and Neutrophil Counts and Maximum Tolerated Dose of Hydroxyurea in Children with Sickle Cell Anemia
Authors: Beverly A Schaefer, Jonathan M Flanagan, Thad A. Howard, Kerri A Nottage, Connie M. Piccone, Scott T. Miller, Alex George, Beatrice E. Gee, Barry R Davis, Russell E. Ware
Journal: Blood (2015)
Polyclonal IgA Gammopathy Associated with Polyclonal Plasmacytosis in Patients Receiving Lenalidomide Maintenance Therapy
Authors: Dmitriy Zamarin, Maria Arcila, Sergio A Giralt, Nikoletta Lendvai, Heather Landau, Alex Lesokhin, David Chung, Danielle Chimento, Hani Hassoun
Journal: Blood (2011)
Signal-Regulatory Protein-α (SIRP- α) Expression Delineates Distinct Subsets in Monocytes/Macrophages in Normal Tissue and in B-Cell Non-Hodgkin Lymphoma
Authors: Ya-Ping Chen, Zhi-Zhang Yang, Jose C. Villasboas, Tammy Price-Troska, Hyo Jin Kim, Anne J. Novak, Stephen M Ansell
Journal: Blood (2016)
New insights into the sensitization to nonspecific lipid transfer proteins from pollen and food: New role of allergen Ole e 7
Authors: Carmen Oeo‐Santos, Ana Navas, Sara Benedé, Berta Ruíz‐León, Araceli Díaz‐Perales, Lothar Vogel, Carmen Moreno‐Aguilar, Aurora Jurado, Mayte Villalba, Rodrigo Barderas
Journal: Allergy (2019)

Abstract Background Ole e 7 is a nonspecific lipid transfer protein (nsLTP) from olive pollen, one of the main allergenic pollens worldwide. This allergenic nsLTP is responsible for severe symptoms in regions with high olive pollen exposure, where many Ole e 7‐sensitized patients exhibit a co‐sensitization to the peach nsLTP, Pru p 3. However, there is no evidence of cross‐reactivity, which explains this observed co‐sensitization. Therefore, the purpose of this study was to explore the relationship between Ole e 7 and Pru p 3. Methods A total of 48 patients sensitized to Ole e 7 and/or Pru p 3 were included in the study. Specific IgE serum levels were measured by ImmunoCAP 250 and ELISA. Inhibition assays were performed to determine the existence of cross‐reactivity between both nsLTPs. Allergic response was analyzed ex vivo (basophil activation test) and in vitro (RBL‐2H3 mast cell model). Results Common IgG and IgE epitopes were identified between both allergens. IgE‐binding inhibition was detected in Ole e 7–monosensitized patients using rPru p 3 as inhibitor, reaching inhibition values of 25 and 100%. Ex vivo and in vitro assays revealed a response against rPru p 3 in four (31%) Ole e 7–monosensitized patients. Conclusions Our results suggest that Ole e 7 could play a new role as primary sensitizer in regions with high olive pollen exposure, leading to the peach nsLTP sensitization. This co‐sensitization process would occur because of the cross‐reactivity between Ole e 7 and Pru p 3 observed in some allergic patients.
A Phase 1/2 Trial of TH-302 and Dexamethasone without or with Bortezomib (TBorD) in Patients with Relapsed/Refractory Multiple Myeloma
Authors: Jacob P. Laubach, Noopur S. Raje, Andrew J. Yee, Philippe Armand, Robert L. Schlossman, Jacalyn Rosenblatt, Jeffrey Matous, Jacquelyn Hedlund, Michael G Martin, Craig Reynolds, Kenneth H. Shain, Ira Zackon, Laura V. Stampleman, Erica N Boswell, Stacey Chuma, Rebecca Liguori, Stephanie Mar, Damian Handisides, Stew Kroll, Kenneth C. Anderson, Paul G. Richardson, Irene M. Ghobrial
Journal: Blood (2014)
Exome Sequencing of Aggressive Natural Killer Cell Leukemia and Drug Profiling Highlight Candidate Driver Pathways in Malignant Natural Killer Cells
Authors: Olli Dufva, Tiina Kelkka, Shady Awad, Nodoka Sekiguchi, Heikki Kuusanmäki, Emma I Andersson, Samuli Eldfors, Disha Malani, Paavo Pietarinen, Leena Saikko, Panu E Kovanen, Junji Suzumiya, Koichi Ohshima, Young Hyeh Ko, Won Seog Kim, Shih-Sung Chuang, Thomas P. Loughran, Wing C Chan, Fumihiro Ishida, Satu Mustjoki
Journal: Blood (2015)
Genetic Response to Lenalidomide in the Circulating Progenitor Cell Compartment of MDS Cohort. Preliminary Results of the Multicenter German LE-MON-5 Study
Authors: Katayoon Shirneshan, Ulrich Germing, Friederike Braulke, Julie Schanz, Uwe Platzbecker, Aristoteles Giagounidis, Florian Nolte, Katharina Götze, Detlef Haase
Journal: Blood (2011)
Dasatinib (Sprycel™) Therapy for Patients with Systemic Mastocytosis.
Authors: Srdan Verstovsek, Hagop Kantarjian, Jorge Cortes, Farhad Ravandi-Kashani, Gautam Borthakur, Claude Nicaise, Inga Sams, Francis Giles, Ayalew Tefferi
Journal: Blood (2006)
Urinary and Serum Angiogenic Markers in Women With Preexisting Diabetes During Pregnancy and Their Role in Preeclampsia Prediction
Authors: Monica Zen, Suja Padmanabhan, Kewei Zhang, Adrienne Kirby, N. Wah Cheung, Vincent W. Lee, Thushari I. Alahakoon
Journal: Diabetes Care (2019)

OBJECTIVE To determine the correlation between urinary and serum placental growth factor (PlGF) and investigate the predictive value as pregnancy progresses of urinary PlGF compared with serum PlGF, soluble fms-like tyrosine kinase 1 (sFLT-1), and the sFLT-1–to–PlGF ratio for the outcome of preeclampsia in women with preexisting diabetes. RESEARCH DESIGN AND METHODS A multicenter prospective cohort study was conducted of 158 women with preexisting insulin-requiring diabetes (41 with type 1 and 117 with type 2). Urinary PlGF and serum PlGF, sFLT-1, and the sFLT-1–to–PlGF ratio were assessed four times (14, 24, 30, and 36 weeks’ gestation), and the association with the outcome of preeclampsia was investigated. RESULTS A correlation between urinary and serum PlGF was demonstrated from 24 weeks’ gestation onward (P &amp;lt; 0.001). At all time points, those who developed preeclampsia had lower serum PlGF levels (P &amp;lt; 0.05), and receiver operating characteristic curves demonstrated that serum PlGF in this cohort performed better than the serum sFLT-1–to–PlGF ratio as a predictive test for preeclampsia. Preconception HbA1c ≥6.5% (48 mmol/mol) was an important discriminative predictor for preeclampsia (P = 0.01). CONCLUSIONS This study prospectively describes the longitudinal changes in urinary PlGF alongside serum angiogenic markers throughout pregnancy in women with preexisting diabetes. We demonstrate correlation between urinary and serum PlGF and that in women with preexisting diabetes in pregnancy, serum PlGF is a better predictor of preeclampsia than the sFLT-1–to–PlGF ratio.
Live Cell Imaging Captures Immune Cell-Mediated Killing of Precursor-B Acute Lymphoblastic Leukemia Cells Targeted with Anti-CD19 (Medi-551) Antibodies: Support for Macrophage and NK Cell In Vivo Activity
Authors: Ksenia Matlawska-Wasowska, Dennis Cook, Samuel R. Stevens, Elizabeth K. Ward, Ronald Herbst, Stuart S. Winter, Bridget S. Wilson
Journal: Blood (2011)